Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations

European Journal of Haematology

Volumn 93, Issue 6, 2014, Pages 533-536

  Guenounou, Sarah ^a   Delabesse, Eric ^a,b   Récher, Christian ^a,b  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Acute myeloid leukemia; All trans retinoid acid; FLT3 ITD mutation; NPM1 mutation; Sorafenib; Targeted therapy

Indexed keywords

AMSACRINE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; SORAFENIB; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; NICOTINAMIDE; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA NERVOSA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CANCER RECURRENCE; CASE REPORT; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CYTOPENIA; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FLT3 ITD GENE; GENE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; INVASIVE ASPERGILLOSIS; LEUKOCYTE COUNT; LEUKOSTASIS; LIVER TOXICITY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NPM1 GENE; SALVAGE THERAPY; SPLENOMEGALY; TRANSPLANTATION CONDITIONING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; ANALOGS AND DERIVATIVES; FATALITY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATAL OUTCOME; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NIACINAMIDE; NUCLEAR PROTEINS; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84911405571     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12334     Document Type: Article

References (23)

1. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86.
2. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
3. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18.
4. Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs 2011;16:407-23.
5. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-71.
6. Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012;26:2353-9.
7. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-98.
8. Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54-60.
9. Schlenk RF, Döhner K, Krauter J, et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia - results of the AMLSG 07-04 randomized treatment trial. Blood 2011;118:(ASH Annual Meeting Abstracts)80.
10. Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008;26:5192-7.
11. Chevallier P, Labopin M, Buchholz S, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012;89:214-9.
12. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089-102.
13. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.
14. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31:3681-7.
15. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92.
16. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012;119:5133-43.
17. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-32.
18. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011;17:1874-7.
19. Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989;3:784-8.
20. Yang GS, Minden MD, McCulloch EA. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 1993;7:1012-9.
21. Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 1994;8:2065-75.
22. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010;115:948-56.
23. Martelli MP, Pettirossi V, Manes N, et al. Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. ASH Annu Meeting Abstr 2007;110:868.